Vol. 3, Issue 1, Part A (2021)

Throughout the SARS-Cov-2 pandemic, multiple interrogations concerning the standard of care of infected patients were raised. Updating and regular sharing of knowledge at national and international levels has been the cornerstone of advancing knowledge and improving the care of these patients. In this case report, we present a thrombo-embolic complication of the viral infection, that manifested Itself with hemodynamic lability, in a patient with a history of ischemic cardiomyopathy treated with acetylsalicylic acid who received high-dose pharmacological thromboprophylaxis. Based on clinical and ultra Sound arguments, the patients received a thrombolytic treatment. Unfortunately, He died 12 hours later. No hemorrhagic complication of the thrombolytic treatment was noted. 
In this article, we will also discuss the diagnostic modalities of thromboembolic events and their pharmacological treatment in infected patients.